NEO Neogenomics Inc

Price (delayed)

$11.16

Market cap

$1.41B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.33

Enterprise value

$1.75B

NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose ...

Highlights
The revenue rose by 2.5% YoY
The gross margin has contracted by 14% YoY
Neogenomics's gross profit has decreased by 12% YoY

Key stats

What are the main financial stats of NEO
Market
Shares outstanding
126.3M
Market cap
$1.41B
Enterprise value
$1.75B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.39
Price to sales (P/S)
2.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.53
Earnings
Revenue
$496.76M
EBIT
-$173.95M
EBITDA
-$95.8M
Free cash flow
-$120.43M
Per share
EPS
-$1.33
Free cash flow per share
-$0.97
Book value per share
$8.05
Revenue per share
$3.99
TBVPS
$6.56
Balance sheet
Total assets
$1.76B
Total liabilities
$742.59M
Debt
$611.58M
Equity
$1.01B
Working capital
$518.36M
Liquidity
Debt to equity
0.6
Current ratio
7.1
Quick ratio
6.54
Net debt/EBITDA
-3.61
Margins
EBITDA margin
-19.3%
Gross margin
35.5%
Net margin
-32.9%
Operating margin
-34.8%
Efficiency
Return on assets
-9%
Return on equity
-15.4%
Return on invested capital
-15.9%
Return on capital employed
-10.4%
Return on sales
-35%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NEO stock price

How has the Neogenomics stock price performed over time
Intraday
-3.04%
1 week
-6.53%
1 month
20.78%
1 year
-47.31%
YTD
20.78%
QTD
20.78%

Financial performance

How have Neogenomics's revenue and profit performed over time
Revenue
$496.76M
Gross profit
$176.33M
Operating income
-$172.81M
Net income
-$163.32M
Gross margin
35.5%
Net margin
-32.9%
The company's operating income has shrunk by 141% YoY
Neogenomics's operating margin has plunged by 135% YoY
The gross margin has contracted by 14% YoY
Neogenomics's gross profit has decreased by 12% YoY

Growth

What is Neogenomics's growth rate over time

Valuation

What is Neogenomics stock price valuation
P/E
N/A
P/B
1.39
P/S
2.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.53
The company's EPS fell by 11% QoQ
The price to book (P/B) is 69% less than the 5-year quarterly average of 4.6 and 21% less than the last 4 quarters average of 1.8
The equity is down by 11% year-on-year and by 2.9% since the previous quarter
The price to sales (P/S) is 58% lower than the 5-year quarterly average of 6.8 and 26% lower than the last 4 quarters average of 3.9
The revenue rose by 2.5% YoY

Efficiency

How efficient is Neogenomics business performance
The return on assets has declined by 14% since the previous quarter
The return on equity has declined by 14% since the previous quarter
NEO's ROIC is down by 12% since the previous quarter
The company's return on sales fell by 9% QoQ

Dividends

What is NEO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NEO.

Financial health

How did Neogenomics financials performed over time
The total assets is 136% greater than the total liabilities
The total assets is down by 8% year-on-year and by 2% since the previous quarter
NEO's current ratio is down by 7% YoY and by 6% from the previous quarter
NEO's debt is 40% lower than its equity
The debt to equity rose by 11% year-on-year
The equity is down by 11% year-on-year and by 2.9% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.